VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Venetoclax combination therapies in AML

Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discusses viable options for combining venetoclax with targeted therapies in acute myeloid leukemia (AML). Specifically outlined is venetoclax combined with ivosidenib, an IDH1 inhibitor, as well as with gilteritinib, a FLT3 inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter